Controlled ovarian hyperstimulation (COH) is an important step during in vitro fertilization
(IVF). Its aim optimally is to recruit 10-15 oocytes. When deciding on the actual treatment,
different stimulation protocols, various stimulating agents and wide range of gonadotropin
dose can one choose from. Prior to the decision on the actual stimulation protocol and
gonadotropin (Gn) dose the patient's expected response to stimulation is assessed primarily
using ovarian reserve markers. Most medications used during stimulation exert their effect in
a dose-dependent manner hence with a higher Gn dose one would expect a better response, more
oocytes. More oocytes could translate into more embryos and potentially a higher pregnancy
rate. The currently available evidence however does not support this practice as randomized
controlled trials (RCT) have failed to show that the use of higher Gn dose results in higher
pregnancy, live-birth rates. These studies however identified patients based on different
criteria, compared different stimulation protocols and various Gn doses. There are only two
RCTs that compared cumulative live birth rates (fresh + frozen embryo transfers) and they
identified poor responders based on different criteria and used different drug regimens.
Therefore, the aim of our study is to compare cumulative IVF clinical pregnancy rates using a
lower and a higher gonadotropin dose among poor responders identified based on universally
accepted criteria.
Description
The investigators will enroll patients who, based on their initial evaluation, reproductive
history or prior fertility treatment, have a proper indication to undergo in vitro
fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) treatment. A basic infertility
evaluation includes: 1.) hormonal evaluation of ovarian function, including ovarian reserve
testing (anti-Müllerian hormone [AMH] level, antral follicle count [AFC]), 2) transvaginal
ultrasound evaluation of female internal genital organs, 3) evaluation of the uterine cavity
(hysterosalpingogram, saline sonohysterogram or hysteroscopy), 4) cervical cancer screening,
5) cervical culture for Chlamydia, 6) serologic testing for HIV, hepatitis B, C, syphilis
(both partners), 7) semen analysis, 8) male andrological exam, 9) if needed male hormonal +/-
genetic testing. IVF-ICSI treatment is started for advanced maternal age, diminished ovarian
reserve (DOR), unexplained infertility after failed intrauterine inseminations, male factor
infertility, endometriosis.
The investigators plan to recruit:
- infertile patients between the ages of 18-42 who require IVF-ICSI treatment and are
identified as poor responders based on: a) AMH: 0.3-1.2 ng/ml or AFC <5, b) AMH>1.2 ng/ml or
AFC≥5 but the retrieval of ≤ 4 oocytes during previous IVF treatment. (POSEIDON category
III-IV, Alviggi et al. Fertility Sterility 2016)
Further inclusion criteria:
- regular menstrual cycles (24-35 days)
- body mass index (BMI): 18-35 kg/m2
- no more than 3 previous failed IVF/ICSI treatments
- no more than 2 previous cancelled stimulations for IVF due to poor response
- motile sperm with normal morphology obtained from the ejaculate or from testicular
biopsy
- intact uterine cavity
Exclusion criteria:
- age <18 or >42 years
- short (<24 days), or long (>35 days) menstrual cycles
- irregular uterine cavity
- presence of hydrosalpinx
- positive HIV, hepatitis B, C screening tests
- BMI <18 or > 35 kg/m2
- planned preimplantation genetic testing of the embryos
- planned elective cryopreservation
- medical, gynecologic or surgical contraindication to IVF treatment
- lack of consent Methods: prospective, multicenter (5 centers), randomized controlled
trial comparing a higher or lower gonadotropin (Gn) dose treatment. In both the low and
high groups two different drug regimens (follitropin alpha + hp human menopausal
gonadotropin or follitropin delta + hp human menopausal gonadotropin) will be used. 150
IU follitropin alpha was shown to be equally effective to 10 mcg follitropin delta.
Therefore, the investigators expect similar response (oocyte yield) with the two
regimens within the high and low Gn dose groups but the study design still will allow
the investigators to compare the two follitropin medications too, which is a secondary
aim.
Lower-dose group:
- 150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)
- 10 mcg follitropin delta + 75 IU hpHMG
Higher-dose group:
- 225 IU follitropin alpha + 150 IU hpHMG
- 15 mcg follitropin delta + 150 IU hpHMG
Treatment protocol:
- The stimulation will get started on day 2 or 3 of the spontaneous menstrual cycle, or on
the 5th day after oral contraceptive pill use or after luteal estradiol pretreatment.
- During the stimulation ultrasound +/- serum hormone measurements will be used to monitor
response. The first ultrasound is scheduled for day 5 or 6 of stimulation. At the time
of the ultrasound blood test for serum estradiol is planned too. At the time of the last
scan serum estradiol and progesterone levels will be measured.
- According to the study protocol the patient will continue with the assigned medication
dose throughout her treatment. Dose increase is not allowed. If there is evidence for
hyper-response [estradiol level > 4000 pmol/l on day 6 or more than 15 follicles over 10
mm any time during the stimulation] the dose can be reduced.
- As soon as two or more follicles reach >17 mm in diameter human chorionic gonadotropin
(hCG) or gonadotropin-releasing hormone agonits [GnRH a] trigger injection will be used
and 35-36 hours later transvaginal ultrasound guided follicle aspiration will be
performed.
- The luteal phase will be supported by vaginal progesterone starting on the day after the
retrieval.
- IVF or ICSI fertilization will be performed based on the semen parameters or previous
fertilization records.
- The day after the retrieval the success of fertilization will be checked and the
embryo(s) will be transferred 2-5 days after the retrieval. Embryo(s) will be
transferred transcervically using soft transfer catheters under ultrasound guidance
using the afterload technique.
- Surplus good quality embryos will be cryopreserved using vitrification. Elective
cryopreservation (no transfer in the fresh cycle) will be performed if: 1) risk of
ovarian hyperstimulation syndrome, 2) serum progesterone level over 1.5 ng/ml [5.5
nmol/l] prior to the oocyte collection, 3) any complications between the retrieval and
planned fresh transfer (bleeding, infection, illness).
- 12-14 days after the transfer serum human chorionic gonadotropin (HCG) measurement will
determine whether implantation has occurred. If the test is positive in 2-3 weeks a
vaginal ultrasound will be done to determine the size, location and number of
gestational sacs. Viable pregnancies will be referred to a formal prenatal care around
week 8-9 of pregnancy. Delivery and perinatal outcome data will be collected by phone
call after the delivery.
- If the fresh IVF cycle is not successful but embryos have been cryopreserved then the
patient will undergo a frozen embryo transfer treatment cycle either in her own cycle,
or in a minimally stimulated or completely artificial cycle.
The care of the patients will not differ from the care of non-study patients in terms of
potential medication dose, the number of clinic visits, retrieval and embryology procedures
as well as prenatal care.
Randomization: Randomization will be performed according to a computer generated list.
(www.randomizer.org) The planned sample size is 700 patients (350 in both the low- and
high-dose groups).
Sample size calculation: In order to determine the sample size, the investigators calculated
with a 20% pregnancy rate in a patient population that fits the inclusion-exclusion criteria.
The investigators expect higher oocyte yield in the higher dose group that should result in
more available embryos and therefore more frozen embryo transfers. The investigators
calculate that this could increase the cumulative pregnancy rate by 50%. The investigators
also believe that about 20% of the patients will drop out for various reasons. Therefore, 350
participants are needed in both arms of the study.
Statistical analysis: After the enrollment of the first 350 patients, a planned interim
analysis will be performed to decide whether the planned sample size is sufficient to achieve
our goal. Logistic regression analysis using a generalized, mixed linear model will be used
to assess the impact of various Gn doses on pregnancy rates. Chi-square test will be used to
test significance and OR will be calculated.
Data will be collected for the following parameters:
- Age
- Cycle day 3 follicle stimulating hormone (FSH), estradiol level
- anti-Müllerian hormone (AMH)
- antral follicle count (AFC)
- Indication for IVF: male, tubal, unexplained, endometriosis, diminished ovarian reserve
- Smoking (yes-no)
- Body mass index
- Cycle number (fresh + frozen together)
- Estradiol level on day 6
- Estradiol + progesterone level at the last scan
- Number of follicles >10 mm at the end of stimulation
- Stimulation duration
- Endometrial thickness
- Gn dose (daily, total)
- Trigger mechanism (HCG vs. GnRh agonist)
- Sperm parameters
- Oocyte number
- Mature (MII) oocyte number
- Proportion of mature oocytes (MII/ oocyte number)
- IVF vs. ICSI fertilization
- Number of fertilized (2 pronuclei (PN)) oocytes
- Fertilization rate per oocyte
- Fertilization rate per mature oocyte
- The number of good quality embryos (morphology better than score "6B2" on day 3, or
score >2BB on day 5) and proportion of good morphology embryos among all embryos
- Number of transferred embryos
- Number of cryopreserved embryos
- Pregnancy rate (positive hCG)
- Clinical pregnancy rate (sac with viable embryo in it)
- Cumulative pregnancy rate (fresh + frozen embryo transfers)
- Pregnancy/ neonatal outcome